



PRODUCT: Moxidectin

COMPANY: Medicines Development for Global Health & TDR

THERAPEUTIC AREA & INDICATION:

New treatment for onchocerciasis (river blindness) demonstrating superiority over ivermectin, the current standard of care against this major neglected infectious disease prevalent in developing countries

ABOUT THE PRODUCT

Moxidectin is the first new medicine to be approved for river blindness (onchocerciasis) in over 30 years. In Phase 3, a single dose of moxidectin reduced skin microfilariae (parasite) levels to undetectable levels one year after treatment in 45.9% of recipients, vs 5.4% in those who received ivermectin. Moxidectin should accelerate elimination of river blindness, and its broad antiparasitic activity make it potentially one of the most important global health medicines in history. Additional Phase 2 and 3 trials are underway in several other important neglected tropical diseases including scabies, lymphatic filariasis, and soil-transmitted helminths.